BARD1 and Miyoshi myopathy: In a group of MM patients treated with high-dose melphalan and ASCT, single nucleotide polymorphisms of Poly (ADP-ribose) Polymerase (PARP), RAD51 Recombinase (RAD51), Proliferating Cell Nuclear Antigen (PCNA), 8-Oxoguanine DNA Glycosylase (OGG1), Xeroderma Pigmentosum, Complementation Group C (XPC), Breast And Ovarian Cancer Susceptibility Protein 1 (BRCA1), Excision Repair 1, Endonuclease Non-Catalytic Subunit (ERCC1), BRCA1 Associated RING Domain 1 (BARD1), and Tumor Protein P53 Binding Protein 1 (TP53BP1) were associated with the outcome and OS of patients [104].